BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/26/2018 2:57:35 PM | Browse: 1049 | Download: 2115
 |
Received |
|
2018-06-09 08:28 |
|
Peer-Review Started |
|
2018-06-10 13:55 |
|
First Decision by Editorial Office Director |
|
2018-07-03 15:51 |
|
Return for Revision |
|
2018-07-12 06:52 |
|
Revised |
|
2018-08-08 06:38 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2018-08-30 08:49 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2018-08-30 17:28 |
|
Articles in Press |
|
2018-08-30 17:28 |
|
Edit the Manuscript by Language Editor |
|
2018-09-10 17:24 |
|
Typeset the Manuscript |
|
2018-10-22 01:22 |
|
Publish the Manuscript Online |
|
2018-10-26 14:57 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Tsung-Jung Lin, Hsi-Chang Lee, Chih-Lin Lin, Chung-Kwe Wang, Kuan-Yang Chen and Deng-Chyang Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Kuan-Yang Chen, MA, Attending Doctor, Department of Gastroenterology, Taipei City Hospital, 11F., No.10, Sec. 4, Renai Rd., Da-an Dist, Taipei 10629, Taiwan. daa13@tpech.gov.tw |
| Key Words |
Helicobacter pylori; Cytochrome P450 2C19; Interleukin-1β; Hybrid therapy; Rabeprazole |
| Core Tip |
In this study, we investigated the efficacy of hybrid therapy as a first-line treatment for Helicobacter pylori eradication and evaluated the independent predictor associated with eradication efficacy, including cytochrome P450 2C19, interleukin-1β (IL-1β)-511 polymorphism and antibiotic resistance. This study is pilot work investigating the impact of the IL-1β-511 polymorphism on the eradication rate of hybrid therapy. |
| Publish Date |
2018-10-26 14:57 |
| Citation |
Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 |
| URL |
http://www.wjgnet.com/2307-8960/full/v6/i12/514.htm |
| DOI |
http://dx.doi.org/10.12998/wjcc.v6.i12.514 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
